Tests Daromun injected into tumors before surgery in people with advanced melanoma
Tests Daromun injected into tumors before surgery in adults with advanced melanoma.
Key facts
- Who runs it
- Philogen S.p.A.
- Where
- Atlanta, Chicago, Columbus, Durham, Easton, Hershey, Houston, Iowa City, La Jolla, New Brunswick, New York, Ney York, Orange, Philadelphia, Phoenix, Richmond, Rochester, Salt Lake City, UT, and Tampa, United StatesSee the 19 sitesAlso in 5 other countries, 35 sites
- Registry title
- Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 186 people, planned
- Started
- 20 Sept 2018
- Expected to end
- Dec 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Daromun
- Surgery
- Adjuvant therapy
- Record updated
- 17 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage IIIB, IIIC or IIID melanoma that can be fully removed by surgery and that has at least one lesion that can be injected.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Stage IIIB, IIIC or IIID melanoma (AJCC 8th edition) in the skin area or nearby lymph nodes, fully removable by surgery. At least one lesion of 10 mm or more across that can be injected, or several lesions adding up to 10 mm or more.
- Earlier treatment
- Earlier treatment such as surgery, radiotherapy, immune checkpoint inhibitors or BRAF/MEK inhibitors is allowed. A 6-week break is needed before joining, and side effects must be Grade 1 or lower. No anti-tumor treatment (except small surgery) in the 4 weeks before joining.
- Biomarker or test result
- Negative tests for HIV, HBV and HCV are needed. Blood counts, liver, kidney and LDH results must be within the limits set by the trial.
Main reasons for not taking part
- Uveal or mucosal melanoma
- Cancer that has spread to distant parts of the body
- Active autoimmune disease
- Serious heart problems or uncontrolled high blood pressure
- Past organ or stem cell transplant
The registry criteria, word for word
Show all 41 criteriaShow less
Who can take part
- Histologically or cytologically confirmed diagnosis of clinical stage IIIB, IIIC, and IIID (AJCC 8th edition) locoregional melanoma that is eligible for complete surgical resection of all metastases (surgically resectable)
- Eligible subjects must have measurable disease and must be candidate for intralesional therapy with at least one injectable cutaneous, subcutaneous, or nodal melanoma lesion (≥ 10 mm in longest diameter) or with multiple injectable lesions that in aggregate have a longest diameter of ≥ 10 mm
- Prior anti-tumor treatment for the primary melanoma lesion, including surgery and approved adjuvant treatments (e.g., radiotherapy, immune checkpoint inhibitors, BRAF/MEK inhibitors, etc.) is allowed. Before enrollment in the study, a wash-out period of 6 weeks is required and toxicities from prior treatments should be resumed to Grade ≤1
- Males or females, age ≥ 18 years
- ECOG Performance Status/WHO Performance Status ≤ 1
- Life expectancy of > 24 months
- Absolute neutrophil count > 1.5 x 109/L
- Hemoglobin > 9.0 g/dL
- Platelets > 100 x 109/L
- Total bilirubin ≤ 30 μmol/L (or ≤ 2.0 mg/dl)
- ALT and AST ≤ 2.5 x the upper limit of normal (ULN)
- Serum creatinine < 1.5 x ULN
- LDH serum level ≤ 1.5 x ULN
- Documented negative test for HIV, HBV and HCV. For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV (i.e. positive anti-HBsAg with not vaccination and/or positive anti-HBcAg Ab), negative serum HBV-DNA is also required
- All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (v4.03) Grade ≤ 1 unless otherwise specified above
- All women of childbearing potential (WOCBP) must have negative pregnancy test results at the screening. WOCBP must be using, from the screening to three months following the last study drug administration, highly effective contraception methods. WOCBP and effective contraception methods are defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomized partner or sexual abstinence. Pregnancy test will be repeated at the safety visit (only WOCBP and only for patients in Arm 1)
- Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception (i.e. spermicidal gel plus condom) from the screening to three months following the last study drug administration
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study
- Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures
Who cannot take part
- Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except: cervical carcinoma in situ, curatively treated basal cell carcinoma, superficial bladder tumors (Ta, Tis \& T1), second primary melanoma in situ or any cancer curatively treated ≥ 5 years prior to study entry
- Presence of active infections (e.g. requiring antimicrobial therapy) or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study
- Recovery from major trauma including surgery within 4 weeks prior to enrollment
- Anti-tumor therapy (except small surgery) within 4 weeks before enrollment
- Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before enrollment
- Planned administration of growth factors or immunomodulatory agents within 7 days before enrollment
- Previous enrolment and randomization in the same study
- History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris
- Inadequately controlled cardiac arrhythmias including atrial fibrillation
- Heart insufficiency (> Grade II, New York Heart Association (NYHA) criteria)
- Uncontrolled hypertension
- Ischemic peripheral vascular disease (Grade IIb-IV)
- Active autoimmune disease
- History of organ allograft or stem cell transplantation
- Known history of allergy to IL2, TNF, or other human proteins/peptides/antibodies or any other constituent of the product
- Patient requiring or taking corticosteroids or other immunosuppressant drugs on a long-term basis will be evaluated case by case with the Sponsor for inclusion/exclusion in the study. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criteria
- Any conditions that in the opinion of the investigator could hamper compliance with the study protocol
- LVEF ≤ 50% and/or abnormalities observed during baseline ECG and Echocardiogram investigations that are considered as clinically significant by the investigator
- Uveal melanoma or mucosal melanoma
- Evidence of distant metastases at screening
- Severe diabetic retinopathy
- Breast feeding female
Where in United States
Also in 5 other countries, 35 sites
- Winship Cancer Institute, Emory UniversityAtlanta, United StatesContact: Michael LoweTaking people
- Rush University Medical CenterChicago, United StatesContact: Sheila Dakhel, PhDNo longer taking part
- Ohio State University Wexner Medical CenterColumbus, United StatesContact: Claire VerschraegenTaking people
- Duke University Medical Center - Duke Cancer CenterDurham, United StatesContact: Georgia BeasleyTaking people
- St. Luke's Cancer Center, Clinical Trial, 3rd floor, 1600 St. Luke's Blvd.Easton, United StatesContact: Sheila Dakhel, PhDNo longer taking part
- Penn State Cancer InstituteHershey, United StatesContact: Joseph DrabickTaking people
- The University of Texas M. D. Anderson Cancer CenterHouston, United StatesContact: Hussein TawbiTaking people
- University of Iowa Hospitals and ClinicsIowa City, United StatesContact: Sheila Dakhel, PhDNo longer taking part
- UC San Diego Moores Cancer CenterLa Jolla, United StatesContact: Sheila Dakhel, PhDNo longer taking part
- Rutgers Cancer Institute, 195 Little Albany StreetNew Brunswick, United StatesContact: Adam BergerTaking people
- Ambulatory Care Center at NYC Langarone HealthNew York, United StatesContact: Sheila Dakhel, PhDNo longer taking part
- Memorial Sloan Kettering Cancer Center - Main CampusNey York, United StatesContact: Danielle BelloTaking people
- UC Irvine Health- Chao Family Comprehensive Cancer CenterOrange, United StatesContact: Sheila Dakhel, PhDNo longer taking part
- Fox Chase Cancer Center 333 Cottman AvenuePhiladelphia, United StatesContact: Jeffrey FarmaTaking people
- Mayo Clinic HospitalPhoenix, United StatesContact: Mahesh Seetharam, MDTaking people
- VCU - McGlothlin Medical Education CenterRichmond, United StatesContact: Andrew PoklepovicTaking people
- Mayo ClinicRochester, United StatesContact: Anastasios Dimou, MDTaking people
- Huntsman Cancer Institute, University of Utah 2000 Circle of HopeSalt Lake City, UT, United StatesContact: John HyngstromTaking people
- Moffitt Cancer CenterTampa, United StatesContact: Jonathan ZagerTaking people
About the trial
What the trial wants to find out
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery and adjuvant therapy).
The 2 groups in the trial
- Daromun plus Surgery and Adjuvant therapyTreatment being tested
Arm-1 patients will follow these steps: 1. screening period, 2. 4-week open-label treatment period, 3. surgery within a maximum of 4 weeks, 4. adjuvant therapy.
Treatment: Daromun, Surgery, and Adjuvant therapy
- Surgery and adjuvant therapyExisting treatment, for comparison
Arm-2 patients will follow these steps: 1. Screening period, 2. direct surgery within 4 weeks from randomization, 3. adjuvant therapy.
Treatment: Surgery and Adjuvant therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C/D Melanoma Patients
- Plain-language title
- Tests Daromun injected into tumors before surgery in people with advanced melanomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Neoadjuvant treatment for stage III and IV cutaneous melanoma.The Cochrane database of systematic reviews, 2023
- Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma.Future oncology (London, England), 2019
- Record updated
- 17 December 2025